https://scholars.lib.ntu.edu.tw/handle/123456789/452396
標題: | Galectin-3 and S100A9: Novel diabetogenic factors mediating pancreatic cancer-associated diabetes | 作者: | WEI-CHIH LIAO Huang B.-S. Yu Y.-H. Yang H.-H. Chen P.-R. Huang C.-C. Huang H.-Y. MING-SHIANG WU LU-PING CHOW |
公開日期: | 2019 | 出版社: | American Diabetes Association Inc. | 卷: | 42 | 期: | 9 | 起(迄)頁: | 1752-1759 | 來源出版物: | Diabetes Care | 摘要: | OBJECTIVE Pancreatic cancer-associated diabetes (PCDM) is a paraneoplastic phenomenon accounting for 1% of new-onset diabetes.We aimed to identify themediators of PCDM and evaluate their usefulness in distinguishing PCDM from type 2 diabetes. RESEARCH DESIGN AND METHODS Secreted proteins of MIA PaCa-2 cells were identified by proteomics, and those with ?10-fold overexpression in transcriptome analysis were assessed by bioinformatics and glucose uptake assay to identify candidate factors. Expression of factors was compared between tumors with and without PCDM by immunohistochemistry. Serum levels were measured in a training set including PC with and without PCDM, type 2 diabetes, pancreatitis, other pancreatic/peripancreatic tumors, and control subjects (n = 50 each). Cutoff values for differentiation between PCDM and type 2 diabetes from the training set were validated in a test set (n = 41 each). RESULTS Galectin-3 and S100A9 were overexpressed in tumors with PCDM and dosedependently suppressed insulin-stimulated glucose uptake in C2C12 myotubes. In the training set, serum galectin-3 and S100A9 levels were exclusively increased in patients with PCDM and distinguished PCDM from type 2 diabetes (area under the curve [AUC] galectin-3: 0.73 [95% CI 0.64-0.83]; S100A9: 0.79 [95% CI 0.70-0.87]). Similar results were observed in the test set (AUC galectin-3: 0.83 [95% CI 0.74-0.92]; S100A9: 0.77 [95% CI 0.67-0.87]), with sensitivity and specificity 72.1% and 86.1%, respectively, for galectin-3 and 69.8% and 58.1% for S100A9 in differentiating between PCDM and type 2 diabetes. CONCLUSIONS Galectin-3 and S100A9 are overexpressed in PCDM tumors and mediate insulin resistance. Galectin-3 and S100A9 distinguish PCDM from type 2 diabetes in subjects with new-onset diabetes. ? 2019 by the American Diabetes Association. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071435180&doi=10.2337%2fdc19-0217&partnerID=40&md5=82d22a41528c3f344da69ad2c8aaf9fe https://scholars.lib.ntu.edu.tw/handle/123456789/452396 |
ISSN: | 01495992 | DOI: | 10.2337/dc19-0217 | SDG/關鍵字: | calgranulin B; galectin 3; insulin; calgranulin B; galectin 3; galectin-3, human; tumor marker; Article; bioinformatics; C2C12 cell line; cancer patient; controlled study; diabetic patient; disease association; disease classification; female; glucose transport; human; human cell; human tissue; immunohistochemistry; insulin resistance; major clinical study; male; MIA PaCa-2 cell line; myotube; non insulin dependent diabetes mellitus; pancreas cancer; protein blood level; protein expression; proteomics; sensitivity and specificity; transcriptomics; adult; blood; complication; differential diagnosis; gene expression profiling; genetics; middle aged; non insulin dependent diabetes mellitus; pancreas tumor; Adult; Biomarkers, Tumor; Calgranulin B; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Galectin 3; Gene Expression Profiling; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Pancreatic Neoplasms; Proteomics; Sensitivity and Specificity |
顯示於: | 生物化學暨分子生物學科研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。